Skip to main content

Advertisement

Table 1 Baseline clinical characteristics of HCV-infected patients included in the present study

From: Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C

Characteristics SVR NR P value Statistics (univariate)
(n = 91 (n = 109) OR(95%CI)
Age mean ± SD (years) 49.7 ± 7.5 51.5 ± 8.5 -  
Gender distribution[n(%)]    -  
 Male 61(67) 68(62.4)   
 Female 30(33) 41(37.6)   
BMI, median (range), kg/m2 23 ± 12 24 ± 13.5 -  
No of injections, median (range) 48(24) 48(67) 0.001 1.035(1.013-1.058)
Tolerability, [n(%)] 91(100) 88(80.7) -
*Adjusted No of injections ,mean ± SEM 39.23 ± 1.179 38.218 ± 1.072 -  
Viral load median, IU/mL 460,000 760,580 0.025 0.637(0.429-0.945)
400,000 IU/mL[n(%)] > Viral load 41(45.1) 38(34.9) -  
Viral load ≥400,000 IU/mL[n(%)] 50(54.9) 71(65.1) -  
aAST median (range), μkat/L 1.66(4.65) 1.44(4.22) -  
bALT median (range), μkat/L 2.04(6.22) 1.7(5.63) -  
Albumin median (range), g/L 39 ± 20 39 ± 22 -  
Bilirubin median (range), μmol/L 13.68 ± 50.45 15.39 ± 44.46 -  
Hemoglobin median (range), g/dL 13 ± 6.1 13.5 ± 7 -  
Platelets median (range), 109/L 190(241) 160(320) 0.012 3.299(1.306-8.334)
cTLC median (range), 109/μL 6(10) 6.4(6) -  
Cholesterol mean ± SD, mmol/L 4.41 ± 0.78 4.69 ± 0.66 -  
Glucose median (range), mmol/L 5.27 ± 3.38 5.5 ± 3.1 -  
Insulin median (range), pmol/L 79.8 ± 127 62.5 ± 147.2 -  
dHOMA-IR median (range) 2.4 ± 5.71 2.2 ± 6.8 -  
eAFP median (range), ng/mL 3.3(29.5) 7(29) <0.001 0.165(0.071-0.383)
25-OH Vitamin D median (range),ng/mL 28 ± 38 19 ± 38 <0.001 4.877(2.512-9.468)
Cirrhosis, [n(%)] 5(5.5) 15(13.7) -  
Fibrosis stage, [n(%)]     
 F1 21(42) 12(18.4) 0.006 3.198(1.378-7.419)
 F2 16(32) 29(44.6) -  
 F3 12(24) 16(24.6) -  
 F4 1(2) 8(12.3) -  
Necroinflammatory grade, [n(%)]     
 A1 26(52) 27(41.5) -  
 A2 22(44) 27(41.5) -  
 A3 2(4) 11(17) 0.04 0.204(0.043-0.97)
IL28B rs12979860 [n(%)]    Chi2 = 55.2 p < 0.001
 C/C 56(61.5) 14(12.8) <0.001 10.857(5.379-21.913)
 C/T 31(34.1) 67(61.5) <0.001 0.324(0.181-0.579)
 T/T 4(4.4) 28(25.7) <0.001 0.133(0.045-0.395)
T allele carriers/ T allele non carriers 35/56 94/14 <0.001 0.092(0.046-0.186)
  1. a AST, aspartate aminotransferase; b ALT, alanine aminotransferase; c TLC, total leukocyte count; d HOMA-IR, homeostatic model of insulin resistance; e AFP, alfa feto protein; NR, non-responders; SVR, sustained virological responders; N, number of samples; OR, odds ratio; 95%CI Confidence Interval.; Chi-square test for genotype distribution; IL28B: interleukin 28 B
  2. *Calculated by general linear model with adjustment for tolerability